- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01929811
NeoMET Study in Neoadjuvant Treatment of Breast Cancer (NeoMET)
Neoadjuvant Treatment of TEC Versus TEC Plus Metformin in Breast Cancer:A Prospective, Randomized Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Neoadjuvant therapy is the standard treatment for locally advanced breast cancer and has adopted in early breast cancer treatment. A meta-analysis showed no difference between neoadjuvant therapy and adjuvant therapy in terms of survival and overall disease progression. Therefore, neoadjuvant treatment can be offered as a standard treatment and as an alternative to adjuvant treatment to all patients who are expected to be candidates for adjuvant systemic chemotherapy. Patients achieved pCR after treatment have superior outcome.
The taxanes were introduced into clinical practice in the early 1990s, and recent meta-analysis showed that compared with anthracycline-containing chemotherapy, taxanes-containing regimens significantly reduced the annual breast cancer recurrences and deaths. Right now, TAC regimen has widely accepted as adjuvant or neoadjuvant chemotherapy regimens in breast cancer treatment.
Metformin, an inexpensive oral agent commonly used to treat type 2 diabetes, has been garnering increasing attention as a potential anti-cancer agent. In neoadjuvant treatment of breast cancer, a retrospective clinical study from MDACC reported a significantly increased pCR rates to standard neoadjuvant chemotherapy in diabetic breast cancer patients who were receiving metformin (24% pCR) compared to diabetics not receiving metformin (8% pCR), with intermediate rates in non-diabetics who did not receive metformin (16% pCR), indicating metformin may increase pCR rate with neoadjuvant chemotherapy.
Base on these data, we initiate a prospective study to evaluate docetaxel, epirubicin and cyclophosphomide (TEC) with TEC plus metformin in neoadjuvant treatment of breast cancer patients. Our aim is to evaluate whether metformin can increase the pCR rate combination with TEC regimen in neoadjuvant setting.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Shandong
-
Linyi, Shandong, China, 276003
- Linyi People's Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Ruijin Hospital, Shanghai Jiaotong University School Of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- women aged ≥18 years and < 70 years with life expectancy > 12 months
- Measurable disease in breast or axillary lymph node, histologically confirmed invasive breast cancer by core needle biopsy, T≥2cm or stage IIb or stage III according AJCC classification, fine-needle aspiration is encouraged to every patient with metastasis suspicious nodes;
- Biopsy specimens are available for ER, PgR, Her2 and proliferation biomarker detection;
- Adequate bone marrow function: Neutrophil ≥ 1.5*109/L; Hb ≥ 100g/L; PLT ≥ 80*109/L;
- Adequate liver and renal function:
- Serum AST ≤ 90U/L
- Bilirubin ≤ upper limit of normal (UNL) range
- Serum creatinine ≤110 umol/L,calculated creatinine clearance should be ≥ 60 mL/min;
- BUN ≤ 7.1mmol/L;
- Has ECOG Performance Score 0-1;
- BMI ≥ 25kg/m2 or hyperglycemia or hyperlipemia or hypertension;
- Willing to take biopsy before neoadjuvant chemotherapy and patients must be accessible for treatment and follow-up;
- Women with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study;
- Written informed consent according to the local ethics committee requirements.
Exclusion Criteria:
- Prior systemic or loco-regional treatment of breast cancer, including chemotherapy;
- Metastatic breast cancer;
- With a history of malignant tumor except uterine cervix cancer in situ or skin basal cell carcinoma;
- Patients with medical conditions that indicate intolerant to neoadjuvant therapy and related treatment, including uncontrolled pulmonary disease, severe infection, active peptic ulcer, coagulation disorder, connective tissue disease or myelo-suppressive disease;
- Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is known to be HIV positive;
- Contraindication for using dexamethasone, chemotherapy agents or metformin;
- History of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction; poorly controlled hypertension (systolic BP >180mmHg or diastolic BP >100mmHg);
- Has peripheral neuropathy ≥ grade 1;
- Patient is pregnant or breast feeding (not willing to stop breast feeding);
- Not willing to take core needle biopsy or patients with psychiatric disorder or other diseases leading to incompliance to the therapy
- Known severe hypersensitivity to any drugs in this study;
- Treatment with any investigational drugs within 30 days before the beginning of study treatment.
- History of lactic or other metabolic acidosis
- Consumption of > 3 alcoholic beverages per day (on average)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Metformin arm
Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6 Metformin: 500mg tid, orally (500mg daily in first cycle)
|
Metformin: 500mg tid, orally (500mg daily in first cycle) on day 1 to day 21 of each 21 day cycle
Other Names:
75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
|
OTHER: TEC
Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6
|
75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pathologic complete response rate
Time Frame: 5 months
|
To compare pathologic complete response (pCR) rate to neoadjuvant chemotherapy between Docetaxel, Epirubicin and Cyclophosphamide (TEC) arm and TEC plus Metformin arm in breast cancer. Definition of pCR is no invasive tumor in primary breast and axillary lymph node. |
5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical response rate
Time Frame: up to 4.5 months
|
To compare the clinical response rate between Docetaxel, Epirubicin and Cyclophosphamide (TEC) arm and TEC plus Metformin arm in breast cancer neoadjuvant treatment.
|
up to 4.5 months
|
safety profile
Time Frame: up to 4.5 months
|
To compare the tolerability and side effects of neoadjuvant chemotherapy between Docetaxel, Epirubicin and Cyclophosphamide (TEC) arm and TEC plus Metformin arm in breast cancer treatment.
|
up to 4.5 months
|
breast conservation therapy (BCT) rate
Time Frame: 5 months
|
5 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kunwei Shen, Dr., Ruijin Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Docetaxel
- Epirubicin
- Metformin
Other Study ID Numbers
- RJBC1301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Safety
-
Anne Estrup OlesenAalborg University; University College of Northern Denmark; Aalborg KommuneRecruitingPatient Safety | Medication SafetyDenmark
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentTerminatedPatient Empowerment | Patient Safety | Medication SafetyNetherlands
-
The University of Texas Health Science Center,...CompletedMedical Education | Patient Safety | Educational Safety Curriculum | Surgical Resident
-
Sun Yat-sen UniversityRecruiting
-
Sonoma Biotherapeutics, Inc.Active, not recruiting
-
MicuRxWellcome Trust; Biomedical Advanced Research and Development AuthorityCompleted
-
Galderma R&DCompleted
-
Recida Therapeutics, Inc.Terminated
-
Creabilis SALCG BioscienceCompleted
-
Korea Otsuka Pharmaceutical Co., Ltd.Recruiting
Clinical Trials on Metformin
-
Anji PharmaSuspendedDiabetes Mellitus, Type 2Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
ShionogiCompleted
-
Bristol-Myers SquibbCompletedType 2 Diabetes MellitusSouth Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
-
Charles University, Czech RepublicCompleted
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States, Mexico, Argentina
-
Hadassah Medical OrganizationWithdrawn
-
Woman'sPfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...WithdrawnInsulin Resistance | Breast Cancer Stage | Racial BiasUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
University Hospital, Basel, SwitzerlandCompletedBecker's Muscular Dystrophy (BMD)Switzerland